CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R. Berenson, Jesús G. Berdeja, Alan Cartmell et al.|Blood|2016Cited by 94
ZNF411, a novel KRAB-containing zinc-finger protein, suppresses MAP kinase signaling pathwayHui Liu, Xiushan Wu, Junmei Zhou et al.|Biochemical and Biophysical Research Communications|2004Cited by 39
Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)James R. Berenson, Jesús G. Berdeja, Alan Cartmell et al.|Blood|2015Cited by 4